DOI QR코드

DOI QR Code

Screening of BRCA1/2 Mutations Using Direct Sequencing in Indonesian Familial Breast Cancer Cases

  • Anwar, Sumadi Lukman (Department of Surgery, Faculty of Medicine Universitas Gadjah Mada) ;
  • Haryono, Samuel J (Department of Surgery, Faculty of Medicine Universitas Gadjah Mada) ;
  • Aryandono, Teguh (Department of Surgery, Faculty of Medicine Universitas Gadjah Mada) ;
  • Datasena, I Gusti Bagus (Department of Surgical Oncology, The National Cancer Center of Dharmais Hospital)
  • Published : 2016.06.01

Abstract

Breast cancer has emerged as the most prevalent cancer among women worldwide, including in Indonesia. The contribution of genes associated with high-risk breast-ovarian cancers, BRCA1 and BRCA2, in the Indonesian population is relatively unknown. We have characterized family history of patients with moderate- to high-risk of breast cancer predisposition in 26 unrelated cases from Indonesia for BRCA1/2 mutation analyses using direct sequencing. Known deleterious mutations were not found in either BRCA1 or BRCA2 genes. Seven variants in BRCA2 were documented in 10 of 26 patients (38%). All variants were categorized as unclassified (VUSs). Two synonymous variants, c.3623A>G and c.4035T>C, were found in 5 patients. One variant, c4600T>C, was found in a 38 year old woman with a family history of breast cancer. We have found 4 novel variants in BRCA2 gene including c.6718C>G, c.3281A>G, c.10176C>G, and c4490T>C in 4 unrelated patients, all of them having a positive family history of breast cancer. In accordance to other studies in Asian population, our study showed more frequent variants in BRCA2 compared to BRCA1. Further studies involving larger numbers of hereditary breast cancer patients are required to reveal contribution of BRCA1/2 mutations and/or other predisposing genes among familial breast cancer patients in Indonesia.

Keywords

Familial breast cancer;BRCA1/2;Indonesian population;germline mutation

Acknowledgement

Supported by : Mochtar Riady Compresehtive Cancer Center (MRCCC) Hospital Siloam Semanggi Jakarta

References

  1. Agarwal G, Ramakant P, Forgach ER, et al (2009). Breast cancer care in developing countries. World J Surg, 33, 2069-2076. https://doi.org/10.1007/s00268-009-0150-z
  2. Akhsan A, Aryandono T, (2010). Prognostic factors of locally advanced breast cancer patients receiving neoadjuvant and adjuvant chemotherapy. Asian Pac J Cancer Prev, 11, 759-61.
  3. Bruin de MA, Kwong A, Goldstein BA, et al (2012). Breast cancer risk factors differ between Asian and white women with BRCA1 / 2 mutations. Fam Cancer, 11, 429-439. https://doi.org/10.1007/s10689-012-9531-9
  4. Brunham LR, Singaraja RR, Pape TD, et al (2005). Accurate prediction of the functional significance of single nucleotide polymorphisms and mutations in the ABCA1 gene. PLoS Genet, 1, 739-747.
  5. Chen S, Parmigiani G (2007). Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol, 25, 1329-33. https://doi.org/10.1200/JCO.2006.09.1066
  6. Daly MB, Axilbund JE, Buys S, et al (2010). Genetic/familial high-risk assessment: breast and ovarian. J Natl Compr Canc Netw, 8, 562-594. https://doi.org/10.6004/jnccn.2010.0043
  7. Gage M, Wattendorf D, Henry LR (2012). Translational advances regarding hereditary breast cancer syndromes. J Surg Oncol, 105, 444-451. https://doi.org/10.1002/jso.21856
  8. Hall MJ, Reid JE, Burbidge LA, et al (2009). BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer. Cancer, 115, 2222-33. https://doi.org/10.1002/cncr.24200
  9. Han, Kim SW, Kang E, et al (2013). The prevalence of BRCA mutations among familial breast cancer patients in Korea: Results of the Korean Hereditary Breast Cancer study. Fam Cancer, 12, 75-81. https://doi.org/10.1007/s10689-012-9578-7
  10. Hartman AR, Kaldate RR, Sailer LM, et al (2012). Prevalence of BRCA mutations in an unselected population of triplenegative breast cancer. Cancer, 118, 2787-95. https://doi.org/10.1002/cncr.26576
  11. He M Di GH, Cao AY, et al (2012). RAD50 and NBS1 are not likely to be susceptibility genes in Chinese non-BRCA1/2 hereditary breast cancer. Breast Cancer Res Treat, 133, 111-6. https://doi.org/10.1007/s10549-011-1700-2
  12. Janavicius R (2010). Founder BRCA1/2 mutations in the Europe: Implications for hereditary breast-ovarian cancer prevention and control. EPMA J, 1, 397-412. https://doi.org/10.1007/s13167-010-0037-y
  13. Jemal A, Bray F, Center MM, et al (2011). Global Cancer Statistics: 2011. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
  14. Kang E, Kim SW (2013). The korean hereditary breast cancer study: review and future perspectives. J Breast Cancer, 16, 245-53. https://doi.org/10.4048/jbc.2013.16.3.245
  15. Kang P, Mariapun S, Phuah SY, et al (2010). Large BRCA1 and BRCA2 genomic rearrangements in Malaysian high risk breast-ovarian cancer families. Breast Cancer Res Treat, 124, 579-84. https://doi.org/10.1007/s10549-010-1018-5
  16. Kim H, Choi DH (2013). Distribution of BRCA1 and BRCA2 mutations in asian patients with breast cancer. J Breast Cancer, 16, 357-365. https://doi.org/10.4048/jbc.2013.16.4.357
  17. Kim H, D'Andrea AD (2012). Regulation of DNA cross-link repair by the Fanconi anemia/BRCA pathway. Genes Dev, 26, 1393-408. https://doi.org/10.1101/gad.195248.112
  18. Kobayashi H, Ohno S, Sasaki Y, Matsuura M (2013). Hereditary breast and ovarian cancer susceptibility genes (Review). Oncol Rep, 30, 1019-29. https://doi.org/10.3892/or.2013.2541
  19. Leeneer de K, Coene I, Crombez B, et al (2012). Prevalence of BRCA1/2 mutations in sporadic breast/ovarian cancer patients and identification of a novel de novo BRCA1 mutation in a patient diagnosed with late onset breast and ovarian cancer: Implications for genetic testing. Breast Cancer Res Treat, 132, 87-95. https://doi.org/10.1007/s10549-011-1544-9
  20. Narod SA (2010). BRCA mutations in the management of breast cancer: The state of the art. Nat Rev Clin Oncol, 7, 702-7. https://doi.org/10.1038/nrclinonc.2010.166
  21. Purnomosari D, Pals G, Wahyono A, et al (2007). BRCA1 and BRCA2 germline mutation analysis in the Indonesian population. Breast Cancer Res Treat, 106, 297-304. https://doi.org/10.1007/s10549-006-9493-4
  22. Ripperger T, Gadzicki D, Meindl A, Schlegelberger B (2009). Breast cancer susceptibility: current knowledge and implications for genetic counselling. Eur J Hum Genet, 17, 722-31. https://doi.org/10.1038/ejhg.2008.212
  23. Roy R, Chun J, Powell SN (2011). BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat Rev Cancer, 12, 68-78. https://doi.org/10.1038/nrc3181
  24. Seong MW, Cho SI, Noh DY, et al (2009). Low contribution of BRCA1/2 genomic rearrangement to high-risk breast cancer in the Korean population. Fam Cancer, 8, 505-8. https://doi.org/10.1007/s10689-009-9279-z
  25. Siegel R, Ma J. Zou Z, Jemal A (2014). Cancer statistics, 2014. CA Cancer J Clin, 64, 9-29. https://doi.org/10.3322/caac.21208
  26. The Breast Cancer Information Core Database (2012). Available at http://research. nhgri.nih.gov/projects/bic/
  27. Tavtigian SV, Deffenbaugh AM, Yin L, et al (2006). Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral. J Med Genet, 43, 295-305.
  28. Tavtigian SV, Byrnes GB, Goldgar DE, Thomas A (2008). Classification of rare missense substitutions, using risk surfaces, with genetic- and molecular-epidemiology applications. Hum Mutat, 29, 1342-54. https://doi.org/10.1002/humu.20896
  29. Zhang B, Beeghly-Fadiel A, Long J, Zheng W (2011). Genetic variants associated with breast-cancer risk: Comprehensive research synopsis, meta-analysis, and epidemiological evidence. Lancet Oncol, 12, 477-488. https://doi.org/10.1016/S1470-2045(11)70076-6